{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0006","upperLimit":"0.049","value":"0.01"},{"groupId":"OG001","lowerLimit":"0.008","upperLimit":"0.077","value":"0.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"description":"Bone marrow response includes complete remission (CR) and partial remission (PR).\n\nComplete remission (CR): Bone marrow showing \\< 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. When erythroid precursors constitute \\< 50% of bone marrow nucleated cells, the percent of blasts is based on all nucleated cells; when there are ≥ 50% erythroid cells, the percent blasts should be based on the non-erythroid cells.\n\nPartial remission (PR): All of the CR criteria (if abnormal prior to treatment), except blasts decreased by 50% over pre-treatment, or a less advanced Myelodysplastic Syndromes (MDS) World Health Organization (WHO) classification than pretreatment. Cellularity and morphology are not relevant.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients randomized to either arm A or arm B","reportingStatus":"POSTED","timeFrame":"Assessed at 16 weeks","title":"Proportion of Patients With Bone Marrow Response","type":"SECONDARY","unitOfMeasure":"proportion of participants"}